Business Description
Cross Country Healthcare, Inc. is a U.S.-based provider specializing in talent management and consultative advisory services for healthcare organizations. The company operates through two main divisions: Nurse and Allied Staffing, and Physician Staffing. The Nurse and Allied Staffing segment offers a broad range of recruitment and personnel solutions under the Cross Country brand. This includes both temporary and direct-hire placements for travel nurses, local nurses, and various allied health professionals. It sources registered nurses, licensed practical nurses, certified nurse assistants, practitioners, and pharmacists for per diem or short-term engagements, as well as clinical and non-clinical specialists for longer contract durations. Additionally, this segment delivers comprehensive workforce solutions, including Managed Service Programs (MSP), Recruitment Process Outsourcing (RPO), and consulting, alongside retained and contingent search services for healthcare professionals. Its diverse clientele spans public and private hospitals (both acute and non-acute care), government facilities, national and local healthcare plans, managed care providers, public and charter schools, outpatient clinics, ambulatory care centers, and physician practice groups. The Physician Staffing segment, operating as Cross Country Locums, focuses on supplying independent contractor physicians across numerous specialties, certified registered nurse anesthetists (CRNAs), nurse practitioners, and physician assistants. These professionals are deployed on temporary assignments to various healthcare environments, such as acute and non-acute care facilities, medical group practices, government establishments, and managed care organizations. Cross Country Healthcare, Inc. was established in 1986 and is headquartered in Boca Raton, Florida.
Business History
Price Overview
Last updated: Jun 27, 2026 10:53am (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -2.93
Total Equity: $322.82M
Shares: 32,409,000
Total Debt: $0.00
Cash: $108.74M
EBITDA: -$64.50M
Total Debt: $0.00
Cash: $108.74M
Revenue: $1.05B
Shares: 32,409,000
Revenue: $1.05B
Revenue: $1.05B
Revenue: $1.05B
Total Equity: $322.82M
Tax Rate: -13.6%
Equity: $322.82M
Total Debt: $0.00
Cash: $108.74M
Current Liabilities: $77.76M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $322.82M
Shares: 32,409,000
Shares: 32,409,000
CapEx: -$8.16M
Shares: 32,409,000
Stock Price: $13.22
Net Income: -$94.85M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 24, 2026 5:53pm (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $1.7B | $2.8B | $2.0B | $1.3B | $1.1B |
| Cost of Revenue | $1.3B | $2.2B | $1.6B | $1.1B | $857.5M |
| Gross Profit | $375.0M | $624.5M | $450.4M | $274.3M | $196.8M |
| Operating Expenses | $235.7M | $354.6M | $337.7M | $291.1M | $200.2M |
| Operating Income | $139.3M | $269.9M | $112.7M | -$16.9M | -$3.5M |
| Net Income | $132.0M | $186.0M | $72.6M | -$14.6M | -$94.9M |
| EBITDA | $154.6M | $280.1M | $129.3M | $16.8M | -$64.5M |
| EPS | $3.60 | $5.09 | $2.07 | $-0.44 | $-2.93 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 24, 2026 5:53pm (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $1.0M | $3.6M | $17.1M | $81.6M | $108.7M |
| Total Current Assets | $508.3M | $675.7M | $415.2M | $335.0M | $293.6M |
| Total Assets | $732.8M | $947.8M | $679.3M | $589.3M | $449.0M |
| Current Liabilities | $199.8M | $271.6M | $148.6M | $120.4M | $77.8M |
| Long-Term Debt | $176.4M | $148.7M | $0 | $0 | $0 |
| Total Liabilities | $435.3M | $490.6M | $205.9M | $170.3M | $126.1M |
| Total Equity | $297.5M | $457.2M | $473.4M | $419.0M | $322.8M |
| Retained Earnings | -$22.7M | $165.7M | $238.4M | $218.1M | $123.2M |
Cash Flow (Annual)
Last updated: Jun 24, 2026 5:53pm (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$85.6M | $134.1M | $248.5M | $120.1M | $48.3M |
| Capital Expenditure | -$7.2M | -$8.8M | -$14.0M | -$8.7M | -$8.2M |
| Free Cash Flow | -$92.8M | $125.3M | $234.5M | $111.4M | $40.1M |
| Acquisitions (net) | -$26.9M | -$35.1M | $199,000 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$2.2M | -$35.3M | -$57.7M | -$37.3M | -$6.8M |
| Net Change in Cash | $-564,000 | $2.6M | $13.5M | $64.5M | $27.1M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 10:08am (44m ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$1.0B $1.0B – $1.0B
|
$1.1B $1.1B – $1.1B
|
$1.1B $1.1B – $1.2B
|
$1.2B $1.2B – $1.2B
|
| EBITDA |
$42.6M $41.8M – $43.4M
|
$44.6M $44.6M – $44.6M
|
$47.3M $46.4M – $48.9M
|
$49.8M $48.9M – $51.5M
|
| Net Income |
$8.3M $6.4M – $10.4M
|
$9.2M $8.2M – $11.6M
|
$19.4M $19.0M – $20.3M
|
$33.4M $32.5M – $34.8M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 24, 2026 5:53pm (2d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +67.2% | -28.0% | -33.5% | -21.6% |
| Gross Profit Growth | +66.5% | -27.9% | -39.1% | -28.2% |
| Operating Income Growth | +93.7% | -58.2% | -115.0% | +79.5% |
| Net Income Growth | +40.9% | -60.9% | -120.0% | -551.6% |
| EBITDA Growth | +81.2% | -53.8% | -87.0% | -484.5% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 10:08am (44m ago)All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-03-31 | Krug Marc S. | A-Award | 21,024.00 | $0.00 | $0 |
| 2026-03-31 | Krug Marc S. | F-InKind | 1,123.00 | $9.40 | $10,556 |
| 2026-03-31 | Krug Marc S. | F-InKind | 1,339.00 | $9.40 | $12,587 |
| 2026-03-31 | Hawkins Amiee Lin | A-Award | 15,958.00 | $0.00 | $0 |
| 2026-03-31 | Hawkins Amiee Lin | F-InKind | 583.00 | $9.40 | $5,480 |
| 2026-03-31 | Hawkins Amiee Lin | F-InKind | 695.00 | $9.40 | $6,533 |
| 2026-03-31 | Clark Kevin Cronin | A-Award | 138,963.00 | $0.00 | $0 |
| 2026-03-31 | Burns William J. | A-Award | 47,873.00 | $0.00 | $0 |
| 2026-03-31 | Burns William J. | F-InKind | 2,423.00 | $9.40 | $22,776 |
| 2026-03-31 | Burns William J. | F-InKind | 2,890.00 | $9.40 | $27,166 |
| 2026-03-31 | Ball Susan E | A-Award | 33,644.00 | $0.00 | $0 |
| 2026-03-31 | Ball Susan E | F-InKind | 1,689.00 | $9.40 | $15,877 |
| 2026-03-31 | Ball Susan E | F-InKind | 2,014.00 | $9.40 | $18,932 |
| 2026-03-31 | Veizaga Marvin | A-Award | 9,043.00 | $0.00 | $0 |
| 2026-03-31 | Veizaga Marvin | F-InKind | 501.00 | $9.40 | $4,709 |
| 2026-03-31 | Veizaga Marvin | F-InKind | 437.00 | $9.40 | $4,108 |
| 2026-03-10 | Veizaga Marvin | 0.00 | $0.00 | $0 | |
| 2026-03-11 | McDonald Colin Patrick | S-Sale | 6,200.00 | $9.70 | $60,146 |
| 2026-01-19 | Hawkins Amiee Lin | 0.00 | $0.00 | $0 | |
| 2025-03-31 | Ball Susan E | F-InKind | 1,740.00 | $14.89 | $25,909 |
Narrative Economics
market-narrative step).